Motor and Sensory Neuropathy Evaluation with Reflex to Titer and Neuronal Immunoblot
2007966
Ordering Recommendation
 
Mnemonic
MSNER
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot
Performed
Thu
Reported
1-9 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Serum separator tube  
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated  
Unacceptable Conditions
Plasma, CSF, or other body fluids. Contaminated, heat-inactivated, hemolyzed, severely icteric, or lipemic specimens.  
Remarks
  
Stability
Ambient: Unacceptable; Refrigerated: 2 weeks; Frozen: 1 year  
Reference Interval
 
 
Test Number Components Reference Interval
 Purkinje Cell/Neuronal Nuclear IgG Scrn None Detected
 Neuronal Nuclear Antibody (ANNA) IFA Titer, IgG Less than 1:10
 Purkinje Cell Antibody, Titer Less than 1:10
2007963Neuronal Nuclear Antibodies (Hu, Ri, Yo) IgG by Immunoblot None Detected
0051285Myelin Associated Glycoprotein (MAG) Antibody, IgM Less than 1000 TU
0051284Sulfate-​3-​Glucuronyl Paragloboside (SGPG) Antibody, IgM Less than 1.00 IV
 Asialo-​GM1 Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
 GM1 Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
 GD1a Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
 GD1b Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
 GQ1b Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
Interpretive Data


See Compliance Statement D: www.aruplab.com/CS
Statement D: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
PCCA/ANNA antibodies are screened by IFA. If the IFA screen is positive at 1:10 or greater, then a titer (PCCA or ANNA) and Immunoblot will be added. Additional charges apply
CPT Code(s)
83516 x 7; 86255; if reflexed add 86256 and  83516
Components
Component Test Code*Component Chart NameLOINC
0051034Asialo-GM1 Antibodies, IgG/IgM44737-5
0051035GM1 Antibodies, IgG/IgM63244-8
0051037GD1a Antibodies, IgG/IgM48656-3
0051038GD1b Antibodies, IgG/IgM26870-6
0051039GQ1b Antibodies, IgG/IgM31674-5
0051284SGPG Antibody, IgM31666-1
0051285MAG Antibody, IgM Elisa17314-6
2007962Purkinje Cell/Neuronal Nuclear IgG Scrn61177-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases